Investing.comQwen · 实盘不做把握 0/10不做原因:已被定价
北京时间·🕒 发布 19:04:38·⟳ 抓取 19:11:41 +7m03s·⚡ 决策 08-28 19:13:04 +1m23s·59.8 天前
FDA 批准礼来 Mounjaro 用于降低 2 型糖尿病高危成人心血管事件风险
事件对礼来方向明确正面,但美股当前处于盘前(07:12 ET),正式开盘为 09:30 ET,距事件发生约 2 小时 18 分钟,信息有充足时间被市场消化;且适应症扩展基于 5 年随访数据、结果早已公开发表(发表于 NEJM),临床结果层面无新增信息,真正的新增只是监管程序性批准落地。在当前时点,开盘后大概率已充分反映,缺乏剩余 edge。
📄 原文Investing.com↗ 原文
Lilly’s Mounjaro wins FDA nod to cut heart attack, stroke risk
Warsh, Nvidia And oil In focus - what’s moving markets INDIANAPOLIS - Eli Lilly and Company (NYSE:LLY) announced today…
不做 Eli Lilly（LLY.US）
临床数据早已公开发表,程序性批准落地时信息已被市场充分消化;美股盘前距正式开盘约 2 小时 18 分钟,开盘时信息已被充分反映,缺乏剩余交易窗口与 edge
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
事实→FDA 批准 Mounjaro 新增 CV 适应症,风险比 0.92 非劣效于 Trulicity。影响链→扩大适应症扩大患者覆盖→对礼来营收有正向边际贡献。价格/证据→临床数据早已发表、程序性批准落地时信息已广为人知;美股盘前距开盘 2+ 小时,开盘时信息已被充分消化。结论→无剩余交易窗口,价格已反映。
🔎 新鲜度:最早出现 2026-08-28 · 扩散 high · price-in 风险 high ↗
关键理由
- Mounjaro 获新增心血管适应症批准,扩大可适用患者人群,对礼来产品商业价值有正向边际贡献
主要风险
- 非劣效而非优效结果,增量商业价值有限;临床数据早已公开,程序性批准落地时信息已被充分消化
反向证据
- 做多前查反向 · 来源 web · 日期 2026-08-28 · 影响 weakens
试验结果为非劣效而非优效,增量商业价值有限
检索:Mounjaro CVOT non-inferior vs superiority 原文 ↗
原文全文
展开原文 · 1,950 字
Warsh, Nvidia And oil In focus - what’s moving markets
INDIANAPOLIS - Eli Lilly and Company (NYSE:LLY) announced today that the U.S. Food and Drug Administration approved Mounjaro (tirzepatide) to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk for such events, according to a press release statement.
The approval allows Mounjaro to lower the risk of cardiovascular death, non-fatal heart attack, or non-fatal stroke in the specified patient population. The drug was already approved to improve blood sugar in adults and children 10 years of age and older with type 2 diabetes.
The FDA decision was based on results from SURPASS-CVOT, a Phase 3 trial that enrolled more than 13,000 participants across 30 countries over approximately five years. The study compared Mounjaro against Trulicity (dulaglutide), a GLP-1 treatment with established cardiovascular benefit.
In the trial, Mounjaro demonstrated non-inferiority to Trulicity with an 8% lower rate of cardiovascular death, heart attack or stroke. The estimated hazard ratio for time to first major adverse cardiovascular event was 0.92 (95.3% CI:0.83, 1.01) for Mounjaro compared to Trulicity. Superiority to Trulicity was not established.
The trial followed participants for a median of 210.1 weeks. The 13,299 participants were randomized to receive either Mounjaro (15 mg or the maximum tolerated dose) or Trulicity (1.5 mg) administered subcutaneously once weekly.
The safety profile of Mounjaro was consistent with previous findings. The most commonly reported adverse events were gastrointestinal-related, generally mild-to-moderate in severity, occurring primarily during dose escalation.
Mounjaro is a dual GIP and GLP-1 receptor agonist. Full results from SURPASS-CVOT were published in The New England Journal of Medicine.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
INDIANAPOLIS - Eli Lilly and Company (NYSE:LLY) announced today that the U.S. Food and Drug Administration approved Mounjaro (tirzepatide) to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk for such events, according to a press release statement.
The approval allows Mounjaro to lower the risk of cardiovascular death, non-fatal heart attack, or non-fatal stroke in the specified patient population. The drug was already approved to improve blood sugar in adults and children 10 years of age and older with type 2 diabetes.
The FDA decision was based on results from SURPASS-CVOT, a Phase 3 trial that enrolled more than 13,000 participants across 30 countries over approximately five years. The study compared Mounjaro against Trulicity (dulaglutide), a GLP-1 treatment with established cardiovascular benefit.
In the trial, Mounjaro demonstrated non-inferiority to Trulicity with an 8% lower rate of cardiovascular death, heart attack or stroke. The estimated hazard ratio for time to first major adverse cardiovascular event was 0.92 (95.3% CI:0.83, 1.01) for Mounjaro compared to Trulicity. Superiority to Trulicity was not established.
The trial followed participants for a median of 210.1 weeks. The 13,299 participants were randomized to receive either Mounjaro (15 mg or the maximum tolerated dose) or Trulicity (1.5 mg) administered subcutaneously once weekly.
The safety profile of Mounjaro was consistent with previous findings. The most commonly reported adverse events were gastrointestinal-related, generally mild-to-moderate in severity, occurring primarily during dose escalation.
Mounjaro is a dual GIP and GLP-1 receptor agonist. Full results from SURPASS-CVOT were published in The New England Journal of Medicine.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。